Alignment Healthcare, Inc. ALHC
7.39 USD +0.39 (+5.57%)
At closeNov 4, 2026, 4:11 AM EST
7.65 +0.26 +3.52%
Pre-market · Nov 4, 4:11 AM ET
6.90 Day range 7.47
6.01 52-week range 25.12
- YTD
- -62.58%
- 1 year
- -56.12%
Analyst view
Consensus: buy
Buy
Price target (mean) 10.79 +46.0% upside
Now 7.39
- Target (low)
- 8.00
- Target (mean)
- 10.79
- Target (high)
- 17.00
Ratings (0m) 15 9 buy · 6 hold · 0 sell
- Strong buy3
- Buy6
- Hold6
- Sell0
- Strong sell0
Recommendation trend
- This month 15
- 1 month ago 15
- 2 months ago 14
- 3 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.17 | -0.19 – -0.14 | -0.00142 | -11871.8% | 1.33B | +31.8% | 4 |
| Next quarter | 0.14667 | 0.13 – 0.16 | 0.1214 | +20.8% | 1.56B | +26.3% | 3 |
| Current year | 0.265 | 0.24 – 0.29 | 0.32142 | -17.5% | 5.22B | +32.1% | 4 |
| Next year | 0.555 | 0.45 – 0.69 | 0.265 | +109.4% | 6.57B | +26.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 30, 2026 | UBS | Maintained | Neutral | Neutral |
| Oct 30, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 30, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Oct 30, 2026 | Keybanc | Downgrade | Overweight | Sector Weight |
| Oct 28, 2026 | Needham | Initiated | — | Hold |
| Oct 12, 2026 | UBS | Maintained | Neutral | Neutral |
| Oct 12, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 9, 2026 | William Blair | Downgrade | Outperform | Market Perform |
| Oct 9, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 9, 2026 | Keybanc | Maintained | Overweight | Overweight |
| Oct 6, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Aug 4, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 3, 2026 | Raymond James | Downgrade | Strong Buy | Outperform |
| May 26, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| May 1, 2026 | UBS | Maintained | Neutral | Neutral |
| May 1, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Feb 5, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jan 16, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jan 14, 2026 | UBS | Maintained | Neutral | Neutral |
| Jan 6, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Dec 17, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Nov 24, 2025 | JP Morgan | Upgrade | Neutral | Overweight |
| Nov 5, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Nov 3, 2025 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Oct 31, 2025 | UBS | Maintained | Neutral | Neutral |
| Oct 14, 2025 | Goldman Sachs | Initiated | — | Buy |
| Aug 25, 2025 | Keybanc | Upgrade | Sector Weight | Overweight |
| Jul 31, 2025 | Barclays | Upgrade | Underweight | Equal-Weight |
| May 2, 2025 | UBS | Maintained | Neutral | Neutral |
